1247885-06-8

Basic information

• Product Name: 4-Piperidinone, 5-broMo-3,3-diMethyl-1-[(4-Methylphenyl)sulfonyl]-
• Synonyms: 4-Piperidinone, 5-broMo-3,3-diMethyl-1-[(4-Methylphenyl)sulfonyl]-;5-BroMo-3,3-diMethyl-1-tosylpiperidin-4-one
• CAS NO: 1247885-06-8
• Molecular Formula: C₁₄H₁₈BrNO₃S
• Molecular Weight: 360.26662
• Mol File: 1247885-06-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Piperidinone, 5-broMo-3,3-diMethyl-1-[(4-Methylphenyl)sulfonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinone, 5-broMo-3,3-diMethyl-1-[(4-Methylphenyl)sulfonyl]-(1247885-06-8)
• EPA Substance Registry System: 4-Piperidinone, 5-broMo-3,3-diMethyl-1-[(4-Methylphenyl)sulfonyl]-(1247885-06-8)

Safety Data

• Hazardous Substances Data: 1247885-06-8(Hazardous Substances Data)

Upstream product

• 648921-37-3 3,3-dimethylpiperidin-4-one hydrochloride 
• 1247885-05-7 3,3-dimethyl-1-tosylpiperidin-4-one 

Downstream Products

• 1247885-07-9 5-azido-3,3-dimethyl-1-tosylpiperidin-4-one 
• 1616709-64-8 2,7,7-trimethyl-5-tosyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 

Relevant articles and documents

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER

Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.

HETEROBICYCLO-SUBSTITUTED-7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formulae A defined herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A receptor.

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.